Search results
Showing 106 to 120 of 356 results for clinical reference medicine & health
Teriflunomide for treating relapsing–remitting multiple sclerosis (TA303)
Evidence-based recommendations on teriflunomide (Aubagio) for treating relapsing–remitting multiple sclerosis in adults.
Evidence summaries: new medicines – Integrated process statement (PMG11)
This integrated process statement has been produced to explain how 'Evidence summaries: new medicines' (ESNMs) are developed. It provides an overview of the key process principles and describes all stages of the development of ESNMs
This quality standard covers diagnosing and managing multiple sclerosis (MS) in adults. It includes care, support and review for people with MS. It describes high-quality care in priority areas for improvement.
View quality statements for QS108Show all sections
This quality standard covers diagnosis of pancreatic cancer and management of pancreatic ductal adenocarcinoma in adults aged over 18. This quality standard describes high-quality care in priority areas for improvement. It does not cover national initiatives, such as cancer screening or audit.
View quality statements for QS177Show all sections
Sections for QS177
- Quality statements
- Quality statement 1: Specialist pancreatic cancer multidisciplinary teams
- Quality statement 2: Staging using FDG-PET/CT
- Quality statement 3: Resectional surgery
- Quality statement 4: Pancreatic enzyme replacement therapy
- Quality statement 5 (placeholder): Effective interventions to address psychological needs
- Update information
- About this quality standard
This quality standard covers recognising, assessing and treating mental health problems in women planning, during or after pregnancy (up to a year after childbirth). It also covers the organisation of mental health services for women during and after pregnancy. It describes high-quality care in priority areas for improvement.
View quality statements for QS115Show all sections
Sections for QS115
- Quality statements
- Quality statement 1: Valproate
- Quality statement 2: Pre-conception information
- Quality statement 3: Information for pregnant women
- Quality statement 4: Asking about mental health and wellbeing
- Quality statement 5: Comprehensive mental health assessment
- Quality statement 6: Psychological interventions
- Quality statement 7 (developmental): Specialist multidisciplinary perinatal mental health services
This quality standard covers diagnosing and managing epilepsies in children, young people and adults. It describes high-quality care in priority areas for improvement.
View quality statements for QS211Show all sections
Sections for QS211
- Quality statements
- Quality statement 1: Referral and assessment after first seizure
- Quality statement 2: Referral to tertiary specialist services
- Quality statement 3: Epilepsy specialist nurse
- Quality statement 4: Epilepsy care plan
- Quality statement 5: Mental health and wellbeing
- Quality statement 6: Neurodevelopment and learning disabilities
- Update information
Upadacitinib for treating moderately to severely active ulcerative colitis (TA856)
Evidence-based recommendations on upadacitinib (Rinvoq) for treating moderately to severely active ulcerative colitis in adults.
Evidence-based recommendations on cobimetinib (Cotellic) with vemurafenib (Zelboraf) for treating unresectable or metastatic melanoma in adults with a BRAF V600 mutation.
Elbasvir–grazoprevir for treating chronic hepatitis C (TA413)
Evidence-based recommendations on elbasvir–grazoprevir (Zepatier) for treating genotype 1 or 4 chronic hepatitis C in adults.
This quality standard covers care after emergency treatment for suspected anaphylaxis, including assessment and referral to specialist allergy services. It describes high-quality care in priority areas for improvement.
View quality statements for QS119Show all sections
Sections for QS119
- Quality statements
- Quality statement 1: Initial education in adrenaline auto-injector use
- Quality statement 2: Referral to specialist allergy services after emergency treatment
- Quality statement 3: Specialist assessment for venom immunotherapy
- Quality statement 4: Ongoing training in adrenaline auto-injector use
- Update information
- About this quality standard
We’re bringing our guidance together by topic, so that it’s all in one place, clearer to understand and easier to use.
This guideline covers assessment, treatment, monitoring and inpatient care for children, young people and adults with eating disorders. It aims to improve the care people receive by detailing the most effective treatments for anorexia nervosa, binge eating disorder and bulimia nervosa.
This quality standard covers the diagnosis and management of constipation of unknown cause in babies, children and young people (from birth to 18 years). It describes high-quality care in priority areas for improvement.
View quality statements for QS62Show all sections
Sections for QS62
- Quality statements
- Quality statement 1: Assessment
- Quality statement 2: First-line treatment with laxatives
- Quality statement 3: Reviewing disimpaction therapy
- Quality statement 4: Reviewing maintenance therapy
- Quality statement 5: Written information
- Quality statement 6: Referral if no response to treatment
- Update information
Evidence-based recommendations on tocilizumab (RoActemra) for treating giant cell arteritis in adults.
Trabectedin for the treatment of advanced soft tissue sarcoma (TA185)
Evidence-based recommendations on trabectedin (Yondelis) for treating advanced soft tissue sarcoma in adults.